Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perleux
- Development stage
- Phase 2
- Lead developer
- Espad Pharmed Daru
- Administration
- Intradermal, Subcutaneous
01
Overview
Perleux is a stabilized, BDDE-free injectable hyaluronic acid (HA) dermal filler developed by the Iranian company Espad Pharmed. It is formulated as a buffered physiological solution containing a hybrid of high molecular weight (H-HA) and low molecular weight (L-HA) hyaluronic acid, with a concentration of 16 mg of each per 1 mL. The product is designed for aesthetic and cosmetic use, including soft-tissue augmentation, wrinkle correction, and facial volumization. Its mechanism of action involves physical tissue augmentation through the intrinsic capacity of hyaluronic acid to bind large amounts of water, thereby restoring moisture, improving skin tone and texture, and treating skin laxity. Perleux is typically administered via intradermal, dermal, or subcutaneous injection into facial bioaesthetic points.
- Brand names
- Perleux
Beyond the preview
Go deeper on Perleux.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Perleux.